title: Selexipag (Uptravi) for pulmonary arterial hypertension.
mesh_terms: D000081:Acetamides / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D000284:Administration, Oral; D000959:Antihypertensive Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D004347:Drug Interactions; D006801:Humans; D006976:Hypertension, Pulmonary / Q000188:drug therapy*; D011719:Pyrazines / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D044006:Receptors, Epoprostenol; D011982:Receptors, Prostaglandin / Q000037:antagonists & inhibitors; D013607:Tablets; D016896:Treatment Outcome
chemical_list: D000081:Acetamides; D000959:Antihypertensive Agents; C113936:PTGIR protein, human; D011719:Pyrazines; D044006:Receptors, Epoprostenol; D011982:Receptors, Prostaglandin; D013607:Tablets; C523468:selexipag